#OCUGENINC News
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST
benzinga.com MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") OCGN, a biotechnology company focused on discovering, developing, and commercializing…
Ocugen Provides Business Update with First Quarter 2024 Financial Results
benzinga.com All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License…
Ocugen to Present at May 2024 Investor Conferences
benzinga.com MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") OCGN, a biotechnology company focused on discovering, developing, and commercializing…